EGFR and hepatocellular carcinoma: As for HCC therapy, CVB‐D primarily attenuated the proliferation and metastasis of HCC cells by regulating the EGFR‐FAK‐AKT/ERK1/2‐Slug signaling pathway and then inducing apoptosis and cell cycle arrest [23].